Press release
MedImmune/AstraZeneca's Benralizumab market size expected to increase many folds by 2032, report DelveInsight
DelveInsight has recently published a report on "Benralizumab Market Forecast Report" providing an in-depth analysis of the Benralizumab market analysis and forecasts up to 2032 in the seven major markets (7MM) (i.e. the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The comprehensive report provides an analysis of Benralizumab market potential and market share analysis in the severe eosinophilic asthma therapeutics space across the 7MM from 2019 to 2032.The report also helps you to understand the Benralizumab clinical and commercial developments along with parameters like the drug's Mechanism of Action (MOA), Route of Administration (ROA), dosage, and special designations.
Interested in finding out the projected market size of Benralizumab by 2032? Visit: https://www.delveinsight.com/report-store/benralizumab-emerging-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Benralizumab Drug Summary
Fasenra (benralizumab) is a monoclonal antibody designed to directly bind to the IL-5 receptor alpha on eosinophils. By doing so, it attracts natural killer cells, triggering rapid and nearly complete depletion of eosinophils through apoptosis (programmed cell death).
AstraZeneca's inaugural respiratory biologic, Fasenra, has received approval as an additional maintenance treatment for severe eosinophilic asthma in the US, EU, Japan, and other regions, with ongoing regulatory reviews in progress. In the US, Fasenra has been granted approval for self-administration using the Fasenra Pen, while in the EU, it is approved for self-administration through either the single-use, prefilled syringe, or the Fasenra Pen. Developed by AstraZeneca and in-licensed from BioWa, Inc., a wholly-owned subsidiary of Kyowa Kirin Co., Ltd., Japan, Fasenra's development involves collaboration between AstraZeneca and its worldwide biologics research and development arm, MedImmune.
Fasenra is now being explored in three new trials for skin diseases, including two phase II trials evaluating its potential in atopic dermatitis (AD) and chronic spontaneous urticaria (CSU), along with a phase III trial focusing on bullous pemphigoid (BP).
Stay ahead of the competition by leveraging key insights and evolving trends in the Benralizumab Market @ https://www.delveinsight.com/sample-request/benralizumab-emerging-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Key Highlights of the Benralizumab Market Report
The report contains forecasted sales evaluation of Benralizumab for severe eosinophilic asthma till 2032.
It provides comprehensive coverage of late-stage emerging therapies for severe eosinophilic asthma treatment.
The report also features qualitative and quantitative analysis with analysts, as well as KOL views for Benralizumab in severe eosinophilic asthma.
Why Benralizumab Market Report?
Leading Benralizumab for severe eosinophilic asthma forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Benralizumab.
A thorough Benralizumab market forecast will help understand how the drug is competing with other emerging therapies in the therapeutics landscape.
It will help to get an analysis of the Benralizumab clinical trial advancements and the detailed clinical assessment, regulatory, and commercial assessment
The report also provides future market assessments for Benralizumab market for severe eosinophilic asthma in the 7 Major Markets, advanced qualitative analysis like SWOT, expert analysts' views, a detailed overview of market competitors, and a short analysis of other emerging therapies in severe eosinophilic asthma.
Request the Sample PDF to Learn More About the Key Offerings of the Report @ https://www.delveinsight.com/sample-request/benralizumab-emerging-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Related Reports By DelveInsight:
Severe Eosinophilic Asthma Market Outlook and Forecast
"Severe Eosinophilic Asthma Market Insights, Epidemiology and Market Forecast 2032" report delivers an in-depth understanding of severe eosinophilic asthma, historical and forecasted epidemiology as well as the severe eosinophilic asthma market trends in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan. It also covers the key companies and emerging therapies in the severe eosinophilic asthma therapeutics landscape.
Top Services Offered By DelveInsight:
Elevate healthcare strategies with Delveinsight Healthcare Consulting. Unlock insights, navigate challenges, and drive success in the dynamic healthcare landscape. https://www.delveinsight.com/consulting
Explore success with our case study on R&D, Manufacturing & Commercial Capabilities. Uncover insights for strategic growth in the industry. https://www.delveinsight.com/case-study/r-and-d-landscape-assessment
Unlock success with our Product Assessment case study. Gain valuable insights for strategic decision-making and product optimization in your industry. https://www.delveinsight.com/case-study/oncology-product-assessment-dashboard
Elevate your business with our Market Assessment case study. Transform insights into strategic actions for success in your industry. https://www.delveinsight.com/case-study/immune-checkpoint-inhibitor-market-potential
428, Corporate Park, Sector-21, Dwarka,
New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release MedImmune/AstraZeneca's Benralizumab market size expected to increase many folds by 2032, report DelveInsight here
News-ID: 3391490 • Views: …
More Releases from DelveInsight Business Research LLP
Alpha-1 Protease Inhibitor Deficiency Market Size 2032: CSL Behring, Grifols The …
DelveInsight's "Alpha-1 Protease Inhibitor Deficiency Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Alpha-1 Protease Inhibitor Deficiency, historical and forecasted epidemiology as well as the Alpha-1 Protease Inhibitor Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Alpha-1 Protease Inhibitor Deficiency Market Research Report
• The increase in Alpha-1 Protease Inhibitor Deficiency Market Size…
Amyloidosis Market Size Report 2032: Attralus Inc., Novotech Pty Limited, Criter …
DelveInsight's "Amyloidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Amyloidosis, historical and forecasted epidemiology as well as the Amyloidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Amyloidosis Market Research Report
• The increase in Amyloidosis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies…
Basal Cell Nevus Syndrome Market Size Report 2032: Latest FDA Approvals, Emergin …
DelveInsight's "Basal Cell Nevus Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Basal Cell Nevus Syndrome, historical and forecasted epidemiology as well as the Basal Cell Nevus Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Key Takeaways from the Basal Cell Nevus Syndrome Market Research Report
• The increase in Basal Cell Nevus Syndrome Market Size…
Biliary Atresia Market Size Report 2032: Latest FDA Approvlas and Pipeline Repor …
DelveInsight's "Biliary Atresia Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Biliary Atresia, historical and forecasted epidemiology as well as the Biliary Atresia market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Key Takeaways from the Biliary Atresia Market Research Report
• The increase in Biliary Atresia Market Size is a direct consequence of the increasing…
More Releases for Benralizumab
Eosinophilic Esophagitis Market to Showcase Strong Growth Prospects Rising at a …
DelveInsight's "Eosinophilic Esophagitis Market" report provides a thorough comprehension of the Eosinophilic Esophagitis, historical and forecasted epidemiology, and the Eosinophilic Esophagitis market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Eosinophilic Esophagitis market report also proffers an analysis of the current Eosinophilic Esophagitis treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
Eosinophilic Esophagitis: An Overview
Eosinophilic Esophagitis (EoE) represents a…
Eosinophilic Esophagitis Treatment Market Size, Industry Trends, Share and Forec …
The global eosinophilic esophagitis treatment market is anticipated to grow at a considerable CAGR of 6.4% during the forecast period (2022-2028). The Increasing prevalence of eosinophilic esophagitis across the globe is one of the prime factors affecting and driving the market for eosinophilic esophagitis treatment. According to the information by the National Institutes of Health (NIH), the Eosinophilic esophagitis incidence increased from 0.01 % in 1995 to 3.16 % per…
Hypereosinophilic Syndrome Drug Market Comprehensive Insight by Growth Rate, Ind …
The global hypereosinophilic syndrome drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Hypereosinophilic syndrome (HES) is a group of blood disorders. It occurs due to the high numbers of eosinophils or white blood cells. Over time, the excess eosinophils enter various tissues which eventually damages the organs. The major factor driving the market growth include the increasing prevalence of hypereosinophilic syndrome across the…
Eosinophilic Esophagitis Drug Market Impact and Opportunities During Coronavirus …
Report Ocean releases its latest report on the global Eosinophilic Esophagitis Drug Market. A combination of information gathered from first-hand sources, qualitative and quantitative assessments of industry analysts, and insights from experts and participants across the value chain is used to calculate the global Eosinophilic Esophagitis Drug Market.
The global eosinophilic esophagitis drug market size is expected to reach US$ 180.5 million by 2028 according to a new study by Report…
Chronic Obstructive Pulmonary Disease Treatment Market Key Findings with Top Com …
Chronic obstructive pulmonary disease (COPD) involves lung inflammation, causing obstruction of airflow from the lungs. It is a chronic disease and symptoms include difficulty in breathing, mucus formation, wheezing, and others. COPD is a progressive lung disease, which includes chronic bronchitis, emphysema, and refractory asthma. Prime causes behind occurrence of chronic obstructive pulmonary disease include smoking, air pollution, secondhand smoke, alpha-1 deficiency-related emphysema (rare form of COPD), and others. There…
Chronic Obstructive Pulmonary Disease Therapeutics - Clinical Trials and Key Pla …
The study analyzed that the chronic obstructive pulmonary disease pipeline comprises 65 drug candidates in different stages of development. Chronic obstructive pulmonary disease is a broad term used for progression of various other diseases that affect the lungs such as, emphysema, chronic bronchitis.
Download free report sample at: https://www.psmarketresearch.com/market-analysis/copd-therapeutics-pipeline-analysis/report-sample
*Human combinatorial antibody library (HuCAL) technology platform for Chronic Obstructive Pulmonary Disease drug development
MorphoSys AG is using human combinatorial antibody library (HuCAL) technology…
